A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

Also called NCT03988920

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 172 participants (enrolled count) (from the registry)
Sponsor
  • Ardelyx Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03988920
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03988920. Non-randomized; no masking; primary purpose treatment. Start 2019-06-15 (actual); primary completion 2021-06-26 (actual). Results posted on 2023-03-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
Acronym
NORMALIZE
Condition
Hyperphosphatemia
Condition
End Stage Renal Disease
Intervention (Drug)
Tenapanor
Intervention (Drug)
Sevelamer Carbonate
Lead sponsor
Ardelyx (class: industry)

Record details

Record id
cardio:ct-nct03988920
Content hash
d4bf2a49f577a5bf67f38bf8c6eb5b6e167b0a5616c1ec95fa071dc412253b1e